Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. - Wikidata - thesis-toulmin - TriplyDB

Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants.

Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants.

http://www.wikidata.org/entity/Q33420904

about

Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Clinical observation of antibiotics in preventing nosocomial infection in premature infants.

P2860

Q38777085-1D2EA2DF-4726-4B57-AC61-4C0ED486CF51 Q40886182-3CC3CBDA-508E-4C11-A2B7-81A15E7B20FB

P2860

Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants.

http://www.wikidata.org/entity/Q33420904

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pharmacokinetics of linezolid ...... n extremely premature infants.

@ast

Pharmacokinetics of linezolid ...... n extremely premature infants.

@en

type

label

Pharmacokinetics of linezolid ...... n extremely premature infants.

@ast

Pharmacokinetics of linezolid ...... n extremely premature infants.

@en

prefLabel

Pharmacokinetics of linezolid ...... n extremely premature infants.

@ast

Pharmacokinetics of linezolid ...... n extremely premature infants.

@en

P1433

Q33420904-2244A9BF-573B-4E23-85AA-11C778B4FB20

P1476

Q33420904-0D5878C7-DD6D-47C4-B29E-6A6A2017AF10

P2093

Q33420904-0B136A54-9C80-4136-AF95-E3EF88CA2F02

Q33420904-2ACB77DB-B0F7-464F-8EB2-149DD19B7C63

Q33420904-35885129-467C-4041-AE50-364365FCC8C6

Q33420904-43524D4C-C1AE-4F6F-A00E-F09013D3EDB9

Q33420904-84BB313A-1763-4863-94E3-483FBFB85568

Q33420904-9033FAB4-FD6B-4AD6-9F78-83373C03827E

Q33420904-EE207D8E-A613-4DBC-8844-6B1A6553B2A7

P2860

Q33420904-05F1DF2B-3A1B-4E17-8399-BE1F7BFDB510

Q33420904-2DE62A21-C7B3-4B07-95FB-90B3FCB4CA96

Q33420904-48C92119-DA47-417C-AC38-2468EC61955F

Q33420904-492E9BB9-894D-4418-B2B9-349060E2007A

Q33420904-50A98340-E79A-4B34-B208-833A02560E44

Q33420904-55B285A1-2E1F-4867-9CF1-19E2914C6BC3

Q33420904-630A73BB-D794-419D-962A-D5E1174B97E4

Q33420904-9170F7C5-B15C-47E2-AD5E-23CE852BA9B8

Q33420904-A4C430A8-2225-4012-8CDB-B9781237CB89

Q33420904-B04A57AE-692C-42F6-B1D3-484BF5E66A61

P2888

Q33420904-3ACF2CD0-A0AD-4515-A0DA-48F50DC875AE

P304

Q33420904-BBE10381-57E2-40DE-B0B3-D2B395A34EB9

P31

Q33420904-1A42024D-A6A2-4D00-B5A4-3A9AB6BF075F

P356

Q33420904-740A1661-9466-4C31-8DFB-03446FB88D30

P433

Q33420904-6AFE472C-6358-4148-AC79-E0AA29C502EF

P478

Q33420904-414ADBAE-4718-4599-9337-4DB29A05B7DC

P50

Q33420904-1536699F-1D84-463C-9C74-433D25AD0B25

Q33420904-1CA2420B-14FC-48AC-8C25-FDA2BCC76ADC

Q33420904-C5389268-D99A-4040-B966-7BAB5FD4DCEB

P577

Q33420904-84F88D08-E74A-4077-957B-301464A658BD

P5875

Q33420904-20D2A8B4-E634-49BF-90DD-E97DF76195F5

P6179

Q33420904-86D5A945-6BC5-4911-AE2A-D095933A0D84

P698

Q33420904-5061E509-1EBA-4CE5-8C3D-DB29168C33A7

P921

Q33420904-3E193319-118A-4C0D-8DB5-068B563116D9

P356

S00228-015-1813-3

P1433

European Journal of Clinical Pharmacology

P1476

Pharmacokinetics of linezolid ...... n extremely premature infants.

@en

P2093

Arnaud Legrand

http://www.w3.org/2001/XMLSchema#string

Christèle Gras-Le Guen

http://www.w3.org/2001/XMLSchema#string

Cédric Jacqueline

http://www.w3.org/2001/XMLSchema#string

Dominique Navas

http://www.w3.org/2001/XMLSchema#string

Guillaume Deslandes

http://www.w3.org/2001/XMLSchema#string

Jocelyne Caillon

http://www.w3.org/2001/XMLSchema#string

Mélanie Sicard

http://www.w3.org/2001/XMLSchema#string

P2860

Hematologic effects of linezolid in young children.

Early and late onset sepsis in late preterm infants.

In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.

Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children.

Linezolid pharmacokinetics in pediatric patients: an overview.

Safety and tolerability of linezolid in children.

Linezolid: effectiveness and safety for approved and off-label indications.

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.

Impact of ontogeny on linezolid disposition in neonates and infants.

Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.

P2888

s00228-015-1813-3

P304

611-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-015-1813-3

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Christophe Rozé

Christèle Gras-Le Guen

P577

2015-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273149132

http://www.w3.org/2001/XMLSchema#string

P6179

1007740655

http://www.w3.org/2001/XMLSchema#string

P698

25740677

http://www.w3.org/2001/XMLSchema#string

P921